CN110636862A - 用于治疗乳腺癌的组合疗法 - Google Patents

用于治疗乳腺癌的组合疗法 Download PDF

Info

Publication number
CN110636862A
CN110636862A CN201880030008.9A CN201880030008A CN110636862A CN 110636862 A CN110636862 A CN 110636862A CN 201880030008 A CN201880030008 A CN 201880030008A CN 110636862 A CN110636862 A CN 110636862A
Authority
CN
China
Prior art keywords
inhibitor
pharmaceutically acceptable
amino
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030008.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·D·卡尔
玛那芙·寇波
娜塔莉·里乌
彼得·盖瑞德·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN110636862A publication Critical patent/CN110636862A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880030008.9A 2017-03-16 2018-03-16 用于治疗乳腺癌的组合疗法 Pending CN110636862A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472345P 2017-03-16 2017-03-16
US62/472,345 2017-03-16
PCT/US2018/022961 WO2018170447A1 (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
CN110636862A true CN110636862A (zh) 2019-12-31

Family

ID=61874039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030008.9A Pending CN110636862A (zh) 2017-03-16 2018-03-16 用于治疗乳腺癌的组合疗法

Country Status (14)

Country Link
US (1) US11083722B2 (enExample)
EP (2) EP3595725B1 (enExample)
JP (1) JP7219224B2 (enExample)
KR (1) KR102517650B1 (enExample)
CN (1) CN110636862A (enExample)
AU (1) AU2018234903B2 (enExample)
BR (1) BR112019019261A2 (enExample)
CA (1) CA3056701A1 (enExample)
IL (1) IL269357B2 (enExample)
MA (1) MA47776A (enExample)
MX (1) MX2019010981A (enExample)
RU (1) RU2764724C2 (enExample)
SG (1) SG11201908531WA (enExample)
WO (1) WO2018170447A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346368B1 (ja) * 2016-11-28 2018-06-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 インダゾール誘導体の塩及びその結晶
AU2019205821C1 (en) 2018-01-08 2025-02-13 Pharmacosmos Holding A/S G1T38 superior dosage regimes
EP4240357A1 (en) * 2020-11-06 2023-09-13 Eisai R&D Management Co., Ltd. Method of treating breast cancer
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196337A1 (en) * 2015-05-29 2016-12-08 Eisai R & D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
IL150638A0 (en) 2000-01-18 2003-02-12 Aventis Pharma Inc Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
DK1252155T3 (da) 2000-01-18 2005-04-04 Aventis Pharma Inc Ethanolsolvat af (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on
AU2001287157A1 (en) 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006077425A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2046330A2 (en) 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
US20090318430A1 (en) 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
LT2632467T (lt) 2010-10-25 2016-09-12 G1 Therapeutics, Inc. Cdk inhibitoriai
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PH12013501940A1 (en) 2011-03-23 2015-12-04 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
RU2015125307A (ru) * 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
HRP20211879T1 (hr) 2013-08-14 2022-03-04 Novartis Ag Kombinirana terapija za liječenje raka
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196337A1 (en) * 2015-05-29 2016-12-08 Eisai R & D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREA ROCCA ET AL.: "Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer", 《EXPERT OPIN PHARMACOTHER》 *
JOSEPH LEHA´R等: "Synergistic drug combinations tend to improve therapeutically relevant selectivity", 《NATURE BIOTECHNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途

Also Published As

Publication number Publication date
BR112019019261A2 (pt) 2020-06-16
RU2764724C2 (ru) 2022-01-19
EP4218820A3 (en) 2023-09-20
IL269357A (en) 2019-11-28
AU2018234903B2 (en) 2024-02-08
MX2019010981A (es) 2020-09-07
IL269357B1 (en) 2024-06-01
EP3595725A1 (en) 2020-01-22
AU2018234903A1 (en) 2019-10-10
US20210113537A1 (en) 2021-04-22
US11083722B2 (en) 2021-08-10
KR20190125448A (ko) 2019-11-06
JP2020510075A (ja) 2020-04-02
RU2019132893A3 (enExample) 2021-06-24
WO2018170447A1 (en) 2018-09-20
MA47776A (fr) 2020-01-22
KR102517650B1 (ko) 2023-04-05
CA3056701A1 (en) 2018-09-20
IL269357B2 (en) 2024-10-01
JP7219224B2 (ja) 2023-02-07
RU2019132893A (ru) 2021-04-16
EP3595725B1 (en) 2023-05-03
SG11201908531WA (en) 2019-10-30
EP4218820A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
TWI798218B (zh) 組合療法
US11083722B2 (en) Combination therapies for the treatment of breast cancer
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
US20230321110A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
JP7372740B2 (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
TW202416992A (zh) 雌激素受體降解劑之給藥方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination